De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.

MLA

Abdelaziz, Ashraf O., et al. “De-Novo versus Recurrent Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy for Hepatitis C Virus.” European Journal of Gastroenterology & Hepatology, vol. 30, no. 1, Jan. 2018, pp. 39–43. EBSCOhost, https://doi.org/10.1097/MEG.0000000000001004.

APA

Abdelaziz, A. O., Nabil, M. M., Abdelmaksoud, A. H., Shousha, H. I., Cordie, A. A., Hassan, E. M., Omran, D. A., Leithy, R., & Elbaz, T. M. (2018). De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus. European Journal of Gastroenterology & Hepatology, 30(1), 39–43. https://doi.org/10.1097/MEG.0000000000001004

Chicago

Abdelaziz, Ashraf O, Mohamed M Nabil, Ahmed H Abdelmaksoud, Hend I Shousha, Ahmed A Cordie, Eman M Hassan, Dalia A Omran, Rania Leithy, and Tamer M Elbaz. 2018. “De-Novo versus Recurrent Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy for Hepatitis C Virus.” European Journal of Gastroenterology & Hepatology 30 (1): 39–43. doi:10.1097/MEG.0000000000001004.